Skye Bioscience (SKYE) Proxy filing summary

Executive summary

• Advanced nimacimab to proof-of-concept in obesity, showing additional weight loss and improved body composition when combined with semaglutide, with a favorable safety profile over 52 weeks.

• Initiated higher-dose expansion of CBeyond to optimize exposure and safety, with plans for Phase 2b incorporating FDA feedback and new delivery technologies.

• Broadened platform with early proof-of-concept for an antibody-peptide conjugate program, reinforcing a multi-mechanism metabolic strategy.

• Maintained capital discipline, focusing resources on key studies, formulation, and regulatory steps to support near-term and long-term value.

• Forward-looking statements highlight execution focus for 2026, with anticipated data readouts and platform advancements.

Voting matters and shareholder proposals

• Election of six directors for a one-year term expiring at the 2027 annual meeting.

• Ratification of CBIZ CPAs P.C. as independent registered public accounting firm for 2026.

• Approval of an amendment to increase authorized common stock from 100,000,000 to 300,000,000 shares.

• Advisory vote on executive compensation (say-on-pay).

• Board recommends voting “FOR” all proposals.

Board of directors and corporate governance

• Board consists of six members, majority independent per Nasdaq standards.

• Chairman and CEO roles are separated for balanced oversight.

• Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members.

• Annual director compensation includes cash and equity, with market benchmarking and annual review.

• Code of Business Conduct and Ethics and Corporate Governance Guidelines in place.